AxoGen (AXGN) Q4 2025 earnings summary

Executive summary

• Achieved Q4 2025 revenue of $59.9 million, up 21.3% year-over-year, and full-year 2025 revenue of $225.2 million, up 20.2% year-over-year.

• FDA Biologics License Approval (BLA) for Avance®, the first and only FDA-approved biologic for peripheral nerve repair, granting 12 years of exclusivity and establishing a new standard of care.

• Raised $133.3 million in a public offering, retired $69.7 million in term loans, and enhanced financial flexibility.

• Strategic focus on growth, market development, commercial expansion, and innovation, with significant investments in sales force and infrastructure.

• Net loss for Q4 2025 was $13.2 million, compared to net income of $0.5 million in Q4 2024; full-year net loss was $15.7 million, versus $10.0 million in 2024.

Financial highlights

• Q4 2025 gross margin was 74.1%, down from 76.1% in Q4 2024; full-year gross margin was 74.3%, down from 75.8% in 2024, impacted by one-time BLA-related costs.

• Adjusted EBITDA for 2025 was $27.9 million (12.4% margin), up from $19.8 million (10.6% margin) in 2024.

• Adjusted net income for Q4 2025 was $3.5 million; full-year adjusted net income was $14.4 million, up from $5.9 million in 2024.

• Cash and investments increased by $6.0 million year-over-year, ending 2025 at $45.5 million.

• Operating expenses rose due to $7.2 million in one-time stock-based compensation tied to BLA approval.

Outlook and guidance

• 2026 revenue expected to grow at least 18% to $265.7 million.

• Gross margin guidance for 2026 is 74%-76%, with improvement expected in 2027 as scale and process efficiencies increase.

• Free cash flow positive for 2026 anticipated, with higher cash burn in Q1.

• Continued disciplined investment in innovation and commercial infrastructure.